Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
The present invention provides a method of treating diseases or disorders benefiting from inactivating or down regulating the activity of the capsaicin receptor in a mammal by inhibiting the activity of the capsaicin receptor. The present invention also provides a method of treating obesity and obesity-related diseases and disorders in a mammal by inhibiting the activity of the capasaicin receptor.
1. A method for treating obesity in a mammal comprising:
administering to the mammal a therapeutically-effective amount of a compound that is a halogenated analog of resiniferatoxin; N-(3-acyloxy-2-benzylpropyl)-N-[4-(methylsulfonylamino)benzyl-thiourea; [N-(4-tert-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea]; [N-(4-tertbutylbenzyl)-N′-[3-fluoro-4-(methylsulfonylamino)benzyl]thiourea; N-(4-chlorobenzyl)-N′-(4-hydroxy-3-iodo-5-methoxybenzyl)thiourea; 4-(3-Chloro-pyridin-2-yl)-piperazine-1-carboxylic acid (4-tert-butyl-phenyl)-amide, or (N-(3-methoxyphenyl)-4-chlorocinnamide.
2. The method according to claim 1 wherein the mammal is a human.
3. The method according to claim 1 , wherein the compound is 4-(3-Chloro-pyridin-2-yl)-piperazine-1-carboxylic acid (4-tert-butyl-phenyl)-amide.
4. A kit for treating obesity in a mammal in need thereof by inactivating or down regulating the activity of the capsaicin receptor, comprising a compound that is a halogenated analog of resiniferatoxin; N-(3-acyloxy-2-benzylpropyl)-N-[4-(methylsulfonylamino)benzyl-thiourea; [N-(4-tert-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea]; [N-(4-tertbutylbenzyl)-N′-[3-fluoro-4-(methylsulfonylamino)benzyl]thiourea; N-(4-chlorobenzyl)-N′-(4-hydroxy-3-iodo-5-methoxybenzyl)thiourea; N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide, or (N-(3-methoxyphenyl)-4-chlorocinnamide.
5. A kit according to claim 4 , wherein the mammal is a human.